Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Toxic

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    634 result(s) found for: Toxic. Displaying page 6 of 32.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2007-000513-12 Sponsor Protocol Number: NR 9284-3 Start Date*: 2007-02-15
    Sponsor Name:Úrazová nemocnice brno
    Full Title: Terlipressin in the treatment of catecholamine-resistant septic shock
    Medical condition: Septic shock refractory to standard dose of norepinephrine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040070 Septic shock LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002411-14 Sponsor Protocol Number: 12576/15 Start Date*: 2015-07-28
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: TRABECTEDIN SINGLE AGENT IN PARTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) PATIENTS: A PROSPECTIVE, PHASE II STUDY
    Medical condition: ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10051938 Ovarian adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003667-35 Sponsor Protocol Number: GBG-97-AMICA Start Date*: 2017-12-29
    Sponsor Name:GBG Forschungs GmbH
    Full Title: Anti-hormonal maintenance treatment with the CDK4/6 inhibitor Ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial
    Medical condition: HR-positive/HER2-negative metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002612-40 Sponsor Protocol Number: TET-SEL Start Date*: 2016-10-20
    Sponsor Name:Department of Oncology Rigshospitalet
    Full Title: A phase II study of selinexor (KPT-330) in patients with advanced thymic epithelial tumour (TET) progressing after primary chemotherapy.
    Medical condition: advanced thymic epithelial tumour (TET) progressing after primary chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043670 Thymoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043674 Thymoma malignant recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061031 Thymoma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019224-31 Sponsor Protocol Number: IGR2009/1593 Start Date*: 2012-06-06
    Sponsor Name:Institut Gustave Roussy
    Full Title: INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS WITH B-CELL NHL OR B-AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTS
    Medical condition: untreated advanced stage B-cell NHL or B-AL.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006595 Burkitt's lymphoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067194 Burkitt's leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Temporarily Halted) NL (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003127-41 Sponsor Protocol Number: BT009E Start Date*: 2021-05-12
    Sponsor Name:INSIGHTEC
    Full Title: Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) with Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carbopla...
    Medical condition: Recurrent Glioblastoma (rGBM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001093-34 Sponsor Protocol Number: ONC-2014-001 Start Date*: 2014-11-25
    Sponsor Name:Istituto Clinico Humanitas
    Full Title: An Open-Label Phase II Study of regorafenib In Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND
    Medical condition: Metastatic Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001187-33 Sponsor Protocol Number: APD811-301 Start Date*: 2019-02-12
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016017-24 Sponsor Protocol Number: 2009-016017-24 Start Date*: 2010-04-07
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A PHASE II RANDOMIZED NON COMPARATIVE STUDY ON THE ACTIVITY OF TRABECTEDIN OR GEMCITABINE + DOCETAXEL IN METASTATIC OR LOCALLY RELAPSED UTERINE LEIOMYOSARCOMA PRETREATED WITH CONVENTIONAL CHEMOT...
    Medical condition: Leiomiosarcomi uterini metastatici o in progressione locale
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046799 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005050-11 Sponsor Protocol Number: SeMMIviD Start Date*: 2019-03-08
    Sponsor Name:A.O. OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI
    Full Title: Effects of Selenium and cholecalciferol on hyperthyroidism due to Graves' disease treated with methimazole: a randomized, clinical, open label, pilot trial
    Medical condition: Graves' disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10020850 Hyperthyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015402-19 Sponsor Protocol Number: Bordet-Erasme-GASTRO-ONCO-002 Start Date*: 2010-02-15
    Sponsor Name:ULB Erasme
    Full Title: Chimiothérapie d’induction suivie d’une radiochimiothérapie préopératoire à base de cisplatine, 5FU et panitumumab dans le traitement des cancers oesogastriques avancés et opérables
    Medical condition: locally advanced oeso-gastric adenocarcinomas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004191-35 Sponsor Protocol Number: GLYCO-1B Start Date*: 2019-04-12
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Evaluation of the safety and efficacy of administration of Empagliflozin in a new treatment for neutropenia in patients with Glycogen Storage Disease type 1b (GSD1b) and G6PC3 deficiency.
    Medical condition: (1) Severe Congenital Neutropenia type 4 (SNC4) due to a deficiency in G6PC3, a phosphatase of the endoplasmic also known a Ubiquitous glucose-6-phosphatase and (2) the neutropenia in Glycogen Sto...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001171-20 Sponsor Protocol Number: CB8025-31735 Start Date*: 2018-11-23
    Sponsor Name:CymaBay Therapeutics, Inc.
    Full Title: A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intole...
    Medical condition: Primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) is a serious and potentially life threatening autoimmune disease of the liver characterized by impaired bile flow (cho...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Temporarily Halted) HU (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000798-31 Sponsor Protocol Number: NEMA-0027-018 Start Date*: 2007-03-02
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: Phase II randomized study of nemorubicin hydrochloride (PNU-152243A) or doxorubicin administered in adult patients with unresectable hepatocellular carcinoma
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-013002-13 Sponsor Protocol Number: PH-L19SIPI131-01/09 Start Date*: 2009-09-25
    Sponsor Name:PHILOGEN S.P.A.
    Full Title: A prospective non-randomized study of 131I-L19SIP Radioimmunotherapy (RIT) in combination with Whole Brain Radiation Therapy (WBRT) in patients with multiple brain metastases from solid tumors
    Medical condition: Patients with multiple brain metastases from solid tumors.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027476 Metastases HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001254-26 Sponsor Protocol Number: 000025 Start Date*: 2012-06-07
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An open label feasibility trial investigating FE 202158 as potential primary vasopressor treatment in patients with vasodilatory hypotension in early septic shock
    Medical condition: Hypotension in early septic shock
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014338-79 Sponsor Protocol Number: CDKO-125a-006 Start Date*: 2009-12-16
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: Phase II study of oral PHA-848125AC in patients with thymic carcinoma previously treated with chemotherapy
    Medical condition: Recurrent or metastatic unresectable thymic carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005219-36 Sponsor Protocol Number: B9E-MC-S378 Start Date*: 2006-03-06
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 2 Single-Arm Study of Gemcitabine in Combination with Oxaliplatin in Pediatric Patients with Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors
    Medical condition: Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000038-33 Sponsor Protocol Number: DF6002-001 Start Date*: 2021-08-25
    Sponsor Name:Dragonfly Therapeutics, Inc.
    Full Title: A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monoth...
    Medical condition: Solid Tumor Melanoma NSCLC Triple-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000290-37 Sponsor Protocol Number: PVP-2016003 Start Date*: 2018-11-21
    Sponsor Name:Provepharm SAS
    Full Title: Open label clinical study to evaluate the safety and efficacy of ProvayBlueTM (methylene blue) for the treatment of acquired methemoglobinemia
    Medical condition: Acquired methemoglobinemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012871 10054290 Acquired methemoglobinemia LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 09:12:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA